P

Pfizer

Makes cancer drugs, vaccines and other medicines

Director/Team Lead - Oncology Field Access & Reimbursement

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
$189.2k - $315.4k/yr
Senior, Expert
Bachelor's, MBA
Remote in USA+1 moreMore locations: New York, NY, USA
RemoteRemote roles; frequent travel within the East region is required.
Business & StrategyBusiness Operations
No H1B Sponsorship

About the job

Requirements
  • Must have a Bachelor's degree and at least 8 years of pharmaceutical industry experience; market access, coding, and reimbursement experience is preferred.
  • Have a general understanding of oncology reimbursement, including oncology payer dynamics, utilization management, government payment systems, patient services/access and reimbursement metrics, specialty pharmacy, co-pay assistance, buy-and-bill reimbursement, and academic versus community provider nuance.
  • Have access and reimbursement experience across both oral and infused/injectable buy-and-bill products.
  • Demonstrate the ability to work in a highly regulated environment and adhere to strict company compliance guidelines and procedures.
  • Be able to clearly define goals and associated outcome metrics and lead a team in executing goals and delivering on metrics.
  • Have matrixed leadership experience, with the demonstrated ability to influence and collaborate cross-functionally.
  • Have a proven track record of collaborating broadly with a diverse range of customers, clients, and stakeholders.
  • Have training in and experience with responsible business communication, both written and spoken.
  • Demonstrate diverse leadership experiences and capabilities, including influencing and collaborating with peers, developing and coaching others, and overseeing and guiding colleagues' work to achieve meaningful outcomes and business impact.
  • Be able to work during Eastern Time Zone hours and travel frequently within the East region.
  • MBA, MHA, MPH, or additional certification in coding and reimbursement is preferred, along with 7+ years of experience.
  • Proven people leadership experience, including management of direct reports, is preferred.
  • Demonstrated experience leading and motivating a team through change is preferred.
  • Oncology market experience is preferred.
  • Excellent written and verbal communication skills are preferred.
  • Exceptional relationship-building skills, including collaboration and networking abilities, are preferred.
  • Ability to work in a team environment is preferred.
  • Must be authorized to be employed in the United States by any employer.
Responsibilities
  • Lead regional execution of field Access & Reimbursement strategies and tactics, and provide insights to Pfizer leadership across Oncology, Pfizer Patient Services, Chief Marketing Office, and other cross-functional partners.
  • Review selected key performance indicator metrics alongside market and access trends to assess regional performance, and coach Field Reimbursement Directors to adjust tactics, execution, or strategy as needed.
  • Design and implement regional adoption of signal-based case prioritization and support the region's transition toward measurement via compliant key performance indicators.
  • Collaborate with Field Reimbursement Directors and other leaders to manage budgets and assign allocations and resources.
  • Prioritize Oncology state societies and manage membership to ensure connectivity to reimbursement professionals.
  • Manage Field Reimbursement Directors' engagement in cross-functional account teams, at Medicare Administrative Carriers, and with accounts.
  • Collaborate with the Oncology Field Access and Reimbursement Leadership team to develop strategy, align on change management approaches, and guide implementation; share successes, best practices, and experiences.
  • Lead Field Reimbursement Directors and set clear accountability for execution of regional strategies and goals.
  • Provide leadership, coaching, and development of Field Reimbursement Director capabilities; manage operational standards, performance evaluation, and compliance.
  • Champion Pfizer's values and ensure colleagues in the region model them.
  • Optimize regional Field Access & Reimbursement support through deployment, alignment, and vacancy management.
  • Coach Field Reimbursement Directors and provide colleague development; manage recruiting and hiring, talent and performance management.
  • Lead and be accountable for regional people-experience processes, including consistent interviewing and hiring practices, annual goal setting and year-end processes such as team performance and year-end reviews, and the annual compensation process, including merit and long-term incentives.
  • Lead and ensure a compliant culture within the region regarding Pfizer policies, procedures, and relevant regulations.
  • Understand the customer, access, and reimbursement landscape, and provide insights and feedback to internal stakeholders to inform Access & Reimbursement strategy.
  • Partner actively with the cross-functional team, as needed and in compliance with Pfizer policies, to optimize appropriate patient support.
  • Gather feedback from Field Reimbursement Director colleagues and provide field perspective to leadership, the Vice President, and the cross-functional team on local access and reimbursement market information and trends.
  • Participate in business planning by providing input and feedback gathered from Field Reimbursement Director colleagues on local market insights and customer knowledge.
  • Maintain technical expertise in access and reimbursement knowledge, customer market perspective, and market knowledge.
  • Develop a thorough understanding of the drivers of local market dynamics.
Desired Qualifications
  • Preference for market access, coding, and reimbursement experience.
  • MBA, MHA, MPH, or additional certification in coding and reimbursement, with 7+ years of experience.
  • Proven people leadership experience, including management of direct reports.
  • Demonstrated experience leading and motivating a team through change.
  • Oncology market experience.
  • Excellent written and verbal communication skills.
  • Exceptional relationship-building skills, including collaboration and networking abilities.
  • Ability to work in a team environment.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.